Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis.

Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Abou-El-Ardat K, Kiefer KC, Hoffmann J, Seeger F, Bonig H, Dimmeler S, Zeiher AM, Rieger MA.

Haematologica. 2019 Nov 7. pii: haematol.2019.224402. doi: 10.3324/haematol.2019.224402. [Epub ahead of print]

2.

Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation.

Ortmann CA, Dorsheimer L, Abou-El-Ardat K, Hoffrichter J, Assmus B, Bonig H, Scholz A, Pfeifer H, Martin H, Schmid T, Brüne B, Scheich S, Steffen B, Riemann J, Hermann S, Dukat A, Bug G, Brandts CH, Wagner S, Serve H, Rieger MA.

Cell Rep. 2019 May 14;27(7):2022-2028.e3. doi: 10.1016/j.celrep.2019.04.064.

3.

Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.

Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid T, Brüne B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM, Rieger MA.

JAMA Cardiol. 2019 Jan 1;4(1):25-33. doi: 10.1001/jamacardio.2018.3965.

4.

Effect of mutation order on myeloproliferative neoplasms.

Kent DG, Ortmann CA, Green AR.

N Engl J Med. 2015 May 7;372(19):1865-6. doi: 10.1056/NEJMc1503143. No abstract available.

PMID:
25946289
5.

Effect of mutation order on myeloproliferative neoplasms.

Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR.

N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.

6.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

7.

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

Ortmann CA, Mazhar D.

Future Oncol. 2013 Nov;9(11):1637-51. doi: 10.2217/fon.13.139. Review.

PMID:
24156324
8.

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron JM, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR.

Blood. 2012 Sep 27;120(13):2704-7. Epub 2012 Aug 16.

9.

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, Bench A, Erber W, Green AR, Huntly BJ.

Blood. 2011 Jul 7;118(1):177-81. doi: 10.1182/blood-2010-12-327593. Epub 2011 May 11.

10.

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M.

Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.

PMID:
21224469
11.

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, Ingle CE, Dermitzakis ET, Campbell PJ, Green AR.

Cancer Cell. 2010 Nov 16;18(5):524-35. doi: 10.1016/j.ccr.2010.10.013.

12.

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.

Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS, Hasselbalch HC, Vannucchi AM, Möller P, Döhner K, Green AR.

Haematologica. 2010 Dec;95(12):2153-6. doi: 10.3324/haematol.2010.029306. Epub 2010 Sep 7.

13.

Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia.

Beer PA, Ortmann CA, Campbell PJ, Green AR.

Blood. 2010 Aug 12;116(6):1013-4. doi: 10.1182/blood-2010-05-284356. No abstract available.

14.

Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.

Ortmann CA, Eisele L, Nückel H, Klein-Hitpass L, Führer A, Dührsen U, Zeschnigk M.

Ann Hematol. 2008 Oct;87(10):809-18. doi: 10.1007/s00277-008-0514-8. Epub 2008 Jun 28.

PMID:
18587578
15.

TERC mutations in children with refractory cytopenia.

Ortmann CA, Niemeyer CM, Wawer A, Ebell W, Baumann I, Kratz CP.

Haematologica. 2006 May;91(5):707-8.

16.

Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.

Ortmann CA, Burchert A, Hölzle K, Nitsche A, Wittig B, Neubauer A, Schmidt M.

Nucleic Acids Res. 2005 Dec 7;33(21):6895-905. Print 2005.

Supplemental Content

Loading ...
Support Center